BIOPHARMA

Is Isomorphic Labs Becoming Pharma’s Foundational AI Platform as Partnerships Surpass $3 Billion and Alphabet Commits $600 Million?

Strategic Overview Isomorphic Labs is emerging as one of the most structurally important AI companies in drug discovery—less…

ByByAnuja Singh Jan 1, 2026

Is Exscientia Setting the Financial Benchmark for AI Drug Discovery with $6B+ in Pharma Commitments?

Strategic Insights Exscientia has emerged as one of the most financially validated AI-drug discovery companies, translating computational precision…

ByByAnuja Singh Jan 1, 2026

Is Insilico Medicine Redefining Drug Discovery as AI Becomes Core to Biopharma Strategy?

Executive Summary Insilico Medicine has emerged as one of the most influential AI-native biotechnology companies, reshaping how the…

ByByAnuja Singh Jan 1, 2026

Can Vanda Pharma’s FDA Approval of Nereus Unlock a New Growth Chapter in Motion-Sickness Treatment?

New York | Jan, 2026 — Vanda Pharmaceuticals Inc. achieved a major regulatory and commercial milestone after the…

ByByAnuja Singh Jan 1, 2026
Image Not Found

Pfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership

Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation.…

ByByAnuja Singh Feb 7, 2026

Eli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution

Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in…

ByByAnuja Singh Feb 7, 2026
Scroll to Top